olmesartan medoxomil ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
angiotensin II receptor antagonists, antihypertensive (non-peptidic) 1985 144689-63-4

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • olmesartan medoxomil
  • olmetec
  • CS-866
  • CS866
Olmesartan blocks the vasoconstrictor effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT1 receptor in vascular smooth muscle.
  • Molecular weight: 558.60
  • Formula: C29H30N6O6
  • CLOGP: 3.54
  • LIPINSKI: 2
  • HAC: 12
  • HDO: 2
  • TPSA: 154.34
  • ALOGS: -4.88
  • ROTB: 11

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
20 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 2 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 1.02 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 26 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

DateAgencyCompanyOrphan
April 25, 2002 FDA DAIICHI SANKYO

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Sprue-like enteropathy 551.58 11 113 30550 410 50574051
Malabsorption 379.91 11 125 30538 3581 50570880
Intestinal villi atrophy 133.19 11 29 30634 150 50574311
Hyperkalaemia 89.26 11 127 30536 47962 50526499
Dehydration 81.88 11 240 30423 152209 50422252
Colitis microscopic 75.85 11 48 30615 6472 50567989
Acute kidney injury 70.39 11 299 30364 227759 50346702
Coeliac disease 63.40 11 48 30615 8637 50565824
Renal failure 62.19 11 173 30490 106460 50468001
Systemic lupus erythematosus 56.07 11 9 30654 140613 50433848
Device related thrombosis 55.28 11 23 30640 1284 50573177
Treatment failure 54.45 11 9 30654 137628 50436833
Diarrhoea 54.24 11 569 30094 587907 49986554
Synovitis 53.97 11 6 30657 123859 50450602
Hyponatraemia 53.14 11 153 30510 95986 50478475
Blood pressure increased 51.08 11 187 30476 132945 50441516
Hypertensive crisis 47.99 11 49 30614 13105 50561356
Drug ineffective 47.01 11 298 30365 819035 49755426
Wound 46.41 11 5 30658 105789 50468672
Infusion related reaction 45.42 11 23 30640 169534 50404927
Off label use 44.26 11 144 30519 474282 50100179
Gallbladder polyp 42.05 11 16 30647 705 50573756
Hypertensive emergency 41.96 11 20 30643 1543 50572918
Completed suicide 41.60 11 14 30649 131875 50442586
Bradycardia 41.02 11 108 30555 64318 50510143
Therapeutic product effect decreased 40.28 11 16 30647 136034 50438427
Cerebral infarction 39.98 11 57 30606 21547 50552914
Maternal exposure during pregnancy 39.43 11 24 30639 159754 50414707
Drug intolerance 39.20 11 45 30618 219059 50355402
Renal impairment 38.55 11 117 30546 75544 50498917
Lower respiratory tract infection 38.15 11 6 30657 95195 50479266
Dizziness 36.15 11 344 30319 346025 50228436
Product use issue 36.12 11 23 30640 149452 50425009
Hypotension 35.96 11 255 30408 235214 50339247
Collagen disorder 34.81 11 10 30653 179 50574282
Contraindicated product administered 34.54 11 24 30639 148934 50425527
Oligohydramnios 33.85 11 28 30635 5722 50568739
Blood urea increased 33.44 11 55 30608 23530 50550931
Metabolic acidosis 30.99 11 71 30592 38754 50535707
Glossodynia 30.45 11 16 30647 115553 50458908
Weight decreased 30.01 11 233 30430 221012 50353449
Blood pressure decreased 29.93 11 88 30575 55821 50518640
Renal disorder 29.78 11 57 30606 27448 50547013
Pancreatic toxicity 29.23 11 6 30657 22 50574439
Toxicity to various agents 28.81 11 53 30610 212446 50362015
Arthropathy 27.62 11 33 30630 157873 50416588
Blood pressure inadequately controlled 27.19 11 22 30641 4358 50570103
Gastritis 27.08 11 61 30602 32922 50541539
Microvillous inclusion disease 26.91 11 5 30658 9 50574452
Swelling 26.43 11 51 30612 200821 50373640
Lymphocytic infiltration 26.35 11 12 30651 834 50573627
Gravitational oedema 25.58 11 13 30650 1152 50573309
Asthenia 25.34 11 300 30363 318742 50255719
Hypokalaemia 25.25 11 113 30550 87879 50486582
Cardiac failure congestive 24.70 11 109 30554 84273 50490188
Joint swelling 24.54 11 72 30591 245214 50329247
Blood creatinine increased 24.31 11 101 30562 76059 50498402
Syncope 24.30 11 125 30538 102877 50471584
Gastrooesophageal reflux disease 22.57 11 99 30564 76329 50498132
Autoimmune enteropathy 21.98 11 4 30659 6 50574455
Putamen haemorrhage 21.91 11 7 30656 182 50574279
Enteritis 21.86 11 24 30639 6971 50567490
Diverticulum 21.12 11 29 30634 10585 50563876
Spleen congestion 20.36 11 6 30657 118 50574343
Pain 19.90 11 240 30423 578663 49995798
Death 19.74 11 116 30547 325263 50249198
Condition aggravated 19.60 11 103 30560 296955 50277506
Heart rate irregular 19.60 11 39 30624 19321 50555140
Eosinophil count 19.23 11 3 30660 0 50574461
Coronary artery disease 19.08 11 50 30613 29676 50544785
Oesophagitis 18.69 11 31 30632 13352 50561109
Discomfort 18.57 11 23 30640 108357 50466104
Burn oesophageal 18.42 11 6 30657 166 50574295
Exposure during pregnancy 18.40 11 28 30635 120987 50453474
Atrial tachycardia 18.31 11 13 30650 2119 50572342
Alopecia 17.87 11 82 30581 244965 50329496
Decreased appetite 17.76 11 193 30470 200730 50373731
Large intestine polyp 17.64 11 22 30641 7310 50567151
Liver disorder 17.50 11 56 30607 37166 50537295
Prerenal failure 17.39 11 11 30652 1482 50572979
Nail disorder 17.06 11 25 30638 9683 50564778
Gastritis erosive 16.71 11 18 30645 5116 50569345
Anti-transglutaminase antibody increased 16.69 11 3 30660 4 50574457
Aortic valve calcification 16.67 11 7 30656 400 50574061
Hyperuricaemia 16.29 11 17 30646 4663 50569798
Chronic kidney disease 16.19 11 57 30606 39714 50534747
Abortion spontaneous 15.92 11 3 30660 41769 50532692
Febrile neutropenia 15.43 11 22 30641 97645 50476816
Hiatus hernia 15.14 11 34 30629 18310 50556151
Oedema peripheral 15.01 11 154 30509 157807 50416654
Azotaemia 14.74 11 15 30648 3993 50570468
Enterocolitis 14.69 11 19 30644 6548 50567913
Product administration error 14.60 11 35 30628 19664 50554797
Distributive shock 14.55 11 8 30655 832 50573629
Helicobacter infection 14.45 11 6 30657 49696 50524765
Blood glucose increased 14.41 11 83 30580 71241 50503220
Electrolyte imbalance 14.37 11 32 30631 17137 50557324
Aortic dissection 14.29 11 10 30653 1593 50572868
Hepatic enzyme abnormal 14.06 11 16 30647 4833 50569628
Hepatorenal failure 14.04 11 7 30656 596 50573865
Skin exfoliation 13.53 11 48 30615 33564 50540897
Acquired oesophageal web 13.48 11 5 30658 205 50574256
Product use in unapproved indication 13.07 11 32 30631 115787 50458674
Chronic gastritis 12.98 11 11 30652 2323 50572138
Abdominal discomfort 12.78 11 85 30578 231556 50342905
Musculoskeletal stiffness 12.62 11 38 30625 128443 50446018
Iron deficiency anaemia 12.57 11 30 30633 16804 50557657
Infection 12.52 11 58 30605 172896 50401565
Chest pain 12.15 11 162 30501 176720 50397741
Hepatitis alcoholic 12.07 11 4 30659 117 50574344
Hypovolaemia 12.00 11 21 30642 9444 50565017
Pharyngeal haematoma 11.96 11 3 30660 31 50574430
Leukopenia 11.91 11 14 30649 67514 50506947
Purpura senile 11.90 11 6 30657 523 50573938
Mucosa vesicle 11.88 11 3 30660 32 50574429
Confabulation 11.82 11 5 30658 291 50574170
Blood creatine phosphokinase increased 11.79 11 39 30624 26328 50548133
Impaired healing 11.75 11 15 30648 69771 50504690
Renal artery stenosis 11.67 11 9 30654 1663 50572798
Withdrawal hypertension 11.67 11 4 30659 130 50574331
Myocardial infarction 11.62 11 93 30570 88934 50485527
Intentional product use issue 11.50 11 18 30645 76900 50497561
General physical health deterioration 11.39 11 46 30617 142388 50432073
Feeling abnormal 11.28 11 121 30542 125371 50449090
Anaemia 11.22 11 215 30448 252241 50322220
Neutropenia 11.08 11 49 30614 147916 50426545
Bradyphrenia 11.04 11 16 30647 6136 50568325

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Sprue-like enteropathy 393.16 11.79 85 20629 355 29553458
Malabsorption 339.67 11.79 102 20612 1846 29551967
Colitis microscopic 79.99 11.79 34 20680 1729 29552084
Gastrointestinal disorder 75.90 11.79 97 20617 28609 29525204
Intestinal villi atrophy 60.99 11.79 15 20699 121 29553692
Renal impairment 57.35 11.79 155 20559 81178 29472635
Coeliac disease 50.41 11.79 18 20696 570 29553243
Death 50.10 11.79 103 20611 341981 29211832
Toxicity to various agents 49.84 11.79 30 20684 173631 29380182
Blood pressure increased 42.66 11.79 131 20583 73672 29480141
Hypotension 39.65 11.79 252 20462 194102 29359711
Dehydration 36.43 11.79 168 20546 114580 29439233
Blood pressure decreased 35.42 11.79 90 20624 45387 29508426
Hepatic function abnormal 35.17 11.79 82 20632 39177 29514636
Dizziness 33.88 11.79 238 20476 189446 29364367
Diarrhoea 32.70 11.79 366 20348 332332 29221481
Off label use 31.45 11.79 107 20607 300693 29253120
Syncope 31.07 11.79 126 20588 81245 29472568
Cerebral infarction 29.55 11.79 58 20656 24617 29529196
Pulmonary hypoplasia 28.98 11.79 11 20703 415 29553398
Hyperkinetic heart syndrome 28.67 11.79 8 20706 110 29553703
Intestinal intraepithelial lymphocytes increased 28.39 11.79 5 20709 4 29553809
Interstitial lung disease 26.67 11.79 95 20619 57623 29496190
Gastrointestinal erosion 26.43 11.79 10 20704 374 29553439
Right atrial hypertrophy 26.41 11.79 11 20703 531 29553282
Hyperkalaemia 24.98 11.79 97 20617 61295 29492518
Weight decreased 24.98 11.79 186 20528 150719 29403094
Hypertensive crisis 24.74 11.79 29 20685 7819 29545994
Microvillous inclusion disease 24.44 11.79 6 20708 48 29553765
Neutropenia 24.40 11.79 34 20680 131677 29422136
Hyperuricaemia 24.33 11.79 27 20687 6862 29546951
Completed suicide 22.65 11.79 18 20696 90228 29463585
Drug abuse 22.60 11.79 14 20700 79869 29473944
Gastrooesophageal reflux disease 22.13 11.79 60 20654 31436 29522377
Transient aphasia 20.77 11.79 6 20708 94 29553719
Anaplastic astrocytoma 19.74 11.79 6 20708 113 29553700
Bronchial wall thickening 19.48 11.79 11 20703 1041 29552772
Drug ineffective 19.03 11.79 163 20551 363007 29190806
Coronary artery occlusion 19.01 11.79 29 20685 10065 29543748
Tropical sprue 18.79 11.79 3 20711 0 29553813
Bronchial secretion retention 18.54 11.79 11 20703 1142 29552671
Haemorrhoids 18.54 11.79 31 20683 11626 29542187
Right ventricular hypertrophy 18.47 11.79 11 20703 1150 29552663
Loss of consciousness 18.23 11.79 101 20613 73955 29479858
Oligohydramnios 17.47 11.79 7 20707 306 29553507
Acute kidney injury 17.27 11.79 271 20443 264996 29288817
Infective exacerbation of chronic obstructive airways disease 17.24 11.79 12 20702 1638 29552175
Product use in unapproved indication 16.50 11.79 22 20692 86853 29466960
Lymphangiectasia intestinal 16.26 11.79 3 20711 4 29553809
Aortic valve stenosis 16.23 11.79 13 20701 2195 29551618
Hypertensive emergency 16.18 11.79 9 20705 827 29552986
Hospitalisation 16.14 11.79 6 20708 45982 29507831
Hypokalaemia 15.52 11.79 73 20641 50130 29503683
Renal failure 15.19 11.79 138 20576 118461 29435352
Collagen disorder 14.86 11.79 5 20709 132 29553681
Gout 14.78 11.79 35 20679 16876 29536937
Pulmonary function test abnormal 14.75 11.79 12 20702 2070 29551743
Atrophy 14.58 11.79 9 20705 1004 29552809
Histology abnormal 14.42 11.79 6 20708 289 29553524
Intestinal ulcer perforation 13.78 11.79 3 20711 13 29553800
Febrile neutropenia 13.77 11.79 37 20677 112203 29441610
Enterocolitis viral 13.77 11.79 4 20710 64 29553749
Obstruction 13.44 11.79 11 20703 1915 29551898
Palmar-plantar erythrodysaesthesia syndrome 13.39 11.79 31 20683 14728 29539085
Echocardiogram abnormal 13.20 11.79 8 20706 863 29552950
Chronic gastritis 13.14 11.79 9 20705 1197 29552616
Rectal ulcer haemorrhage 12.94 11.79 4 20710 80 29553733
Treatment failure 12.66 11.79 5 20709 36934 29516879
Hypertension 12.62 11.79 131 20583 116483 29437330
Erosive duodenitis 12.49 11.79 9 20705 1298 29552515
Gastric cancer 12.34 11.79 16 20698 4778 29549035
Cerebral haemorrhage 12.24 11.79 49 20665 31377 29522436
Thrombocytopenia 12.06 11.79 51 20663 134772 29419041
Prerenal failure 12.03 11.79 10 20704 1778 29552035
Herpes ophthalmic 11.91 11.79 6 20708 451 29553362
Product administration error 11.84 11.79 29 20685 14281 29539532

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Sprue-like enteropathy 908.61 10.54 194 41406 835 64456297
Malabsorption 545.26 10.54 174 41426 4229 64452903
Intestinal villi atrophy 184.87 10.54 44 41556 334 64456798
Colitis microscopic 147.23 10.54 79 41521 7353 64449779
Dehydration 101.55 10.54 339 41261 216424 64240708
Hyperkalaemia 101.02 10.54 210 41390 100919 64356213
Coeliac disease 94.08 10.54 59 41541 7353 64449779
Renal impairment 90.67 10.54 240 41360 134777 64322355
Diarrhoea 88.38 10.54 779 40821 721925 63735207
Gastrointestinal disorder 74.50 10.54 173 41427 89536 64367596
Toxicity to various agents 74.28 10.54 75 41525 363438 64093694
Completed suicide 69.28 10.54 29 41571 224385 64232747
Hypertensive crisis 68.41 10.54 71 41529 18177 64438955
Renal failure 67.05 10.54 263 41337 181425 64275707
Cerebral infarction 66.22 10.54 105 41495 40939 64416193
Hypotension 63.10 10.54 441 41159 380533 64076599
Off label use 62.48 10.54 205 41395 632601 63824531
Hypertensive emergency 56.03 10.54 28 41572 2248 64454884
Syncope 55.59 10.54 225 41375 157410 64299722
Acute kidney injury 55.57 10.54 486 41114 448754 64008378
Blood pressure increased 53.63 10.54 237 41363 172315 64284817
Microvillous inclusion disease 49.66 10.54 11 41589 58 64457074
Synovitis 48.87 10.54 4 41596 99086 64358046
Drug ineffective 48.78 10.54 330 41270 839917 63617215
Blood pressure decreased 48.74 10.54 144 41456 86055 64371077
Collagen disorder 48.49 10.54 14 41586 239 64456893
Weight decreased 47.97 10.54 332 41268 285407 64171725
Death 47.83 10.54 156 41444 482549 63974583
Hyperuricaemia 44.35 10.54 43 41557 10148 64446984
Device related thrombosis 43.65 10.54 23 41577 2062 64455070
Treatment failure 43.23 10.54 11 41589 116805 64340327
Hepatic function abnormal 42.80 10.54 114 41486 64199 64392933
Gastrooesophageal reflux disease 40.60 10.54 132 41468 83011 64374121
Hypokalaemia 39.82 10.54 170 41430 121733 64335399
Maternal exposure during pregnancy 37.52 10.54 8 41592 95876 64361256
Dizziness 37.47 10.54 433 41167 429730 64027402
Gallbladder polyp 37.44 10.54 16 41584 896 64456236
Enteritis 34.90 10.54 41 41559 12036 64445096
Drug intolerance 34.80 10.54 42 41558 187950 64269182
Hyponatraemia 34.77 10.54 188 41412 148151 64308981
Blood pressure inadequately controlled 33.93 10.54 28 41572 5356 64451776
Cardiac failure congestive 33.71 10.54 170 41430 130410 64326722
Renal disorder 33.60 10.54 72 41528 35293 64421839
Infusion related reaction 33.45 10.54 34 41566 164433 64292699
Bradycardia 32.72 10.54 157 41443 118062 64339070
Tropical sprue 31.74 10.54 5 41595 0 64457132
Diverticulum 30.42 10.54 40 41560 13158 64443974
Contraindicated product administered 30.07 10.54 16 41584 107813 64349319
Gastritis 29.83 10.54 77 41523 42541 64414591
Prerenal failure 29.66 10.54 21 41579 3201 64453931
Pericarditis 29.54 10.54 3 41597 62513 64394619
Therapeutic product effect decreased 29.50 10.54 19 41581 115332 64341800
Product use issue 29.03 10.54 33 41567 151682 64305450
Hyperkinetic heart syndrome 28.67 10.54 8 41592 120 64457012
Interstitial lung disease 28.66 10.54 132 41468 97600 64359532
Intestinal intraepithelial lymphocytes increased 27.36 10.54 5 41595 7 64457125
Chronic gastritis 27.27 10.54 20 41580 3220 64453912
Right atrial hypertrophy 27.23 10.54 11 41589 534 64456598
Blood urea increased 27.11 10.54 76 41524 44077 64413055
Chronic kidney disease 26.53 10.54 90 41510 57829 64399303
Lower respiratory tract infection 26.44 10.54 14 41586 94600 64362532
Drug abuse 26.20 10.54 28 41572 132346 64324786
Decreased appetite 26.19 10.54 287 41313 281002 64176130
Febrile neutropenia 26.02 10.54 51 41549 187606 64269526
Exposure during pregnancy 25.67 10.54 9 41591 77666 64379466
Systemic lupus erythematosus 25.63 10.54 9 41591 77603 64379529
Lymphocytic infiltration 25.24 10.54 14 41586 1390 64455742
Wound 25.03 10.54 9 41591 76468 64380664
Hiatus hernia 24.21 10.54 45 41555 19912 64437220
Neutropenia 23.98 10.54 77 41523 239547 64217585
Pemphigus 23.88 10.54 5 41595 60696 64396436
Large intestine polyp 23.68 10.54 32 41568 10805 64446327
Product use in unapproved indication 23.63 10.54 49 41551 176569 64280563
Pulmonary function test abnormal 23.23 10.54 18 41582 3146 64453986
Obstruction 22.81 10.54 18 41582 3230 64453902
Liver disorder 22.78 10.54 81 41519 53270 64403862
Aortic dissection 21.85 10.54 18 41582 3434 64453698
Autoimmune enteropathy 21.00 10.54 5 41595 38 64457094
Asthenia 20.97 10.54 390 41210 427654 64029478
Gravitational oedema 20.44 10.54 13 41587 1659 64455473
Arthropathy 20.35 10.54 29 41571 120938 64336194
Joint swelling 20.32 10.54 71 41529 215311 64241821
Pain 19.92 10.54 245 41355 553266 63903866
Haemorrhoids 19.59 10.54 46 41554 23955 64433177
Blood creatinine increased 19.44 10.54 152 41448 135630 64321502
Pulmonary hypoplasia 19.43 10.54 5 41595 54 64457078
Aortic valve stenosis 19.32 10.54 19 41581 4561 64452571
Exercise lack of 18.98 10.54 8 41592 433 64456699
Anaplastic astrocytoma 18.82 10.54 6 41594 145 64456987
Putamen haemorrhage 18.81 10.54 8 41592 443 64456689
Swelling 18.57 10.54 48 41552 160170 64296962
Enterocolitis 18.36 10.54 30 41570 11988 64445144
Gastrointestinal erosion 18.23 10.54 10 41590 972 64456160
Infective exacerbation of chronic obstructive airways disease 18.18 10.54 14 41586 2424 64454708
Metabolic acidosis 18.03 10.54 92 41508 70866 64386266
Transient aphasia 18.02 10.54 6 41594 167 64456965
Right ventricular hypertrophy 18 10.54 11 41589 1309 64455823
Erosive duodenitis 17.95 10.54 12 41588 1666 64455466
Condition aggravated 17.84 10.54 154 41446 372272 64084860
Cerebral haemorrhage 17.25 10.54 72 41528 51018 64406114
Gluten sensitivity 17.25 10.54 7 41593 344 64456788
Myocardial infarction 17.20 10.54 173 41427 165648 64291484
Diabetic nephropathy 17.14 10.54 14 41586 2640 64454492
Hypersensitivity 17.06 10.54 67 41533 196385 64260747
Gastric cancer 17.05 10.54 21 41579 6472 64450660
Atrial fibrillation 17.04 10.54 177 41423 170912 64286220
Hypoalbuminaemia 16.81 10.54 36 41564 17638 64439494
Nail disorder 16.66 10.54 24 41576 8600 64448532
Leukocyturia 16.46 10.54 11 41589 1527 64455605
Coronary artery occlusion 16.45 10.54 31 41569 13860 64443272
Gout 16.36 10.54 40 41560 21373 64435759
Hypertension 16.26 10.54 246 41354 259015 64198117
Heart rate irregular 15.67 10.54 46 41554 27367 64429765
Chest pain 15.61 10.54 226 41374 235754 64221378
Rheumatoid arthritis 15.60 10.54 54 41546 164240 64292892
Infection 15.45 10.54 64 41536 184816 64272316
Lymphangiectasia intestinal 15.43 10.54 3 41597 7 64457125
Renal cyst haemorrhage 15.40 10.54 7 41593 455 64456677
Ileal ulcer 15.30 10.54 9 41591 999 64456133
Bradyphrenia 15.08 10.54 24 41576 9382 64447750
Rhabdomyolysis 15.00 10.54 106 41494 91620 64365512
Musculoskeletal stiffness 14.98 10.54 36 41564 123170 64333962
Anti-transglutaminase antibody increased 14.89 10.54 3 41597 9 64457123
Glossodynia 14.78 10.54 12 41588 64684 64392448
Hospitalisation 14.77 10.54 16 41584 75191 64381941
Presyncope 14.74 10.54 53 41547 35036 64422096
Gastritis erosive 14.72 10.54 24 41576 9571 64447561
Encephalopathy 14.61 10.54 10 41590 58809 64398323
Histology abnormal 14.55 10.54 6 41594 307 64456825
Bronchial wall thickening 14.33 10.54 11 41589 1896 64455236
Skin exfoliation 14.18 10.54 62 41538 44823 64412309
Intentional product use issue 14.02 10.54 25 41575 95339 64361793
Autoimmune hepatitis 13.84 10.54 24 41576 10060 64447072
Bradykinesia 13.77 10.54 19 41581 6541 64450591
Iron deficiency anaemia 13.75 10.54 38 41562 21851 64435281
Coronary artery disease 13.74 10.54 76 41524 60357 64396775
Polyp 13.52 10.54 19 41581 6654 64450478
General physical health deterioration 13.47 10.54 77 41523 204348 64252784
Hypocalcaemia 13.44 10.54 58 41542 41695 64415437
Blood potassium increased 13.36 10.54 42 41558 25938 64431194
Lymphocytosis 13.34 10.54 14 41586 3630 64453502
Intestinal ulcer perforation 13.22 10.54 3 41597 18 64457114
Hypomagnesaemia 12.87 10.54 53 41547 37323 64419809
Leukopenia 12.78 10.54 29 41571 101213 64355919
Anaemia 12.75 10.54 327 41273 378353 64078779
Aortic valve calcification 12.73 10.54 7 41593 683 64456449
Oedema peripheral 12.20 10.54 197 41403 210120 64247012
Atrophy 12.19 10.54 10 41590 1897 64455235
Normochromic normocytic anaemia 12.03 10.54 18 41582 6672 64450460
Gastrointestinal hypermotility 12.00 10.54 5 41595 263 64456869
Generalised oedema 11.93 10.54 35 41565 20818 64436314
Duodenitis 11.92 10.54 18 41582 6723 64450409
Hypovolaemia 11.90 10.54 29 41571 15457 64441675
Disease progression 11.86 10.54 49 41551 141631 64315501
Atrial tachycardia 11.84 10.54 13 41587 3546 64453586
Loss of consciousness 11.83 10.54 147 41453 148218 64308914
Drug resistance 11.71 10.54 4 41596 35098 64422034
Mucosa vesicle 11.69 10.54 3 41597 32 64457100
Bronchial secretion retention 11.63 10.54 11 41589 2516 64454616
Disturbance in attention 11.59 10.54 6 41594 41068 64416064
Acquired oesophageal web 11.57 10.54 5 41595 288 64456844
Diabetes mellitus inadequate control 11.45 10.54 35 41565 21286 64435846
Thalamus haemorrhage 11.43 10.54 9 41591 1610 64455522
Duodenal ulcer haemorrhage 11.35 10.54 17 41583 6308 64450824
Hepatitis acute 11.30 10.54 26 41574 13363 64443769
Hypoglycaemia 10.92 10.54 97 41503 89795 64367337
Paranasal sinus haematoma 10.88 10.54 3 41597 43 64457089
Peripheral swelling 10.67 10.54 85 41515 209068 64248064
Diverticulum intestinal 10.63 10.54 18 41582 7402 64449730
Embolic stroke 10.59 10.54 17 41583 6694 64450438

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC C09CA08 CARDIOVASCULAR SYSTEM
AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN
Angiotensin II receptor blockers (ARBs), plain
ATC C09DA08 CARDIOVASCULAR SYSTEM
AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS
Angiotensin II receptor blockers (ARBs) and diuretics
ATC C09DB02 CARDIOVASCULAR SYSTEM
AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS
Angiotensin II receptor blockers (ARBs) and calcium channel blockers
ATC C09DX03 CARDIOVASCULAR SYSTEM
AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS
Angiotensin II receptor blockers (ARBs), other combinations
FDA MoA N0000000070 Angiotensin 2 Receptor Antagonists
FDA EPC N0000175561 Angiotensin 2 Receptor Blocker
MeSH PA D047228 Angiotensin II Type 1 Receptor Blockers
MeSH PA D057911 Angiotensin Receptor Antagonists
MeSH PA D000959 Antihypertensive Agents
MeSH PA D002317 Cardiovascular Agents
CHEBI has role CHEBI:35674 antihypertensive drugs
CHEBI has role CHEBI:61016 angiotensin receptor antagonists

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Hypertensive disorder indication 38341003 DOID:10763
Chronic heart failure off-label use 48447003
Atrial fibrillation off-label use 49436004 DOID:0060224
Diastolic heart failure off-label use 418304008 DOID:9775
Nondiabetic Proteinuric Nephropathy off-label use
Anuria contraindication 2472002 DOID:2983
Hypercholesterolemia contraindication 13644009
Hyperkalemia contraindication 14140009
Secondary angle-closure glaucoma contraindication 21571006
Hypovolemia contraindication 28560003
Dehydration contraindication 34095006
Hyperuricemia contraindication 35885006 DOID:1920
Angioedema contraindication 41291007 DOID:1558
Hypokalemia contraindication 43339004
Diabetes mellitus type 2 contraindication 44054006 DOID:9352
Low blood pressure contraindication 45007003
Systemic lupus erythematosus contraindication 55464009 DOID:9074
Sympathectomy contraindication 57071006
Hepatic failure contraindication 59927004
Hypercalcemia contraindication 66931009 DOID:12678
Hyperparathyroidism contraindication 66999008 DOID:13543
Hypochloremic alkalosis contraindication 70134007
Hepatic coma contraindication 72836002 DOID:12550
Diabetes mellitus contraindication 73211009 DOID:9351
Chronic idiopathic constipation contraindication 82934008
Hyponatremia contraindication 89627008
Gout contraindication 90560007 DOID:13189
Kidney disease contraindication 90708001 DOID:557
Hypomagnesemia contraindication 190855004
Acute pancreatitis contraindication 197456007 DOID:2913
Neonatal hyperbilirubinemia contraindication 281610001
Pregnancy, function contraindication 289908002
Renal artery stenosis contraindication 302233006
Azotemia contraindication 445009001
Severe Aortic Valve Stenosis contraindication




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 4.25 acidic
pKa2 5.76 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Type-1 angiotensin II receptor GPCR ANTAGONIST IC50 8.10 IUPHAR CHEMBL
Type-1 angiotensin II receptor GPCR IC50 8.09 CHEMBL

External reference:

IDSource
4021345 VUID
N0000179505 NUI
D01204 KEGG_DRUG
4021344 VANDF
4021345 VANDF
C0386393 UMLSCUI
CHEBI:31932 CHEBI
CHEBI:48416 CHEBI
OLM PDB_CHEM_ID
CHEMBL1200692 ChEMBL_ID
D000068557 MESH_DESCRIPTOR_UI
C437965 MESH_SUPPLEMENTAL_RECORD_UI
591 IUPHAR_LIGAND_ID
7787 INN_ID
144689-24-7 SECONDARY_CAS_RN
6M97XTV3HD UNII
130881 PUBCHEM_CID
158781 PUBCHEM_CID
DB00275 DRUGBANK_ID
118463 RXNORM
16642 MMSL
245076 MMSL
d04801 MMSL
009634 NDDF
009635 NDDF
385540001 SNOMEDCT_US
412259001 SNOMEDCT_US
412260006 SNOMEDCT_US
C1098320 UMLSCUI
CHEMBL1516 ChEMBL_ID
8612 INN_ID
8W1IQP3U10 UNII

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 3 0093-5002 TABLET, FILM COATED 40 mg ORAL ANDA 26 sections
Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 3 0093-5003 TABLET, FILM COATED 40 mg ORAL ANDA 26 sections
Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 3 0093-5004 TABLET, FILM COATED 40 mg ORAL ANDA 26 sections
Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 3 0093-5005 TABLET, FILM COATED 20 mg ORAL ANDA 26 sections
Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 3 0093-5006 TABLET, FILM COATED 40 mg ORAL ANDA 26 sections
OLMESARTAN MEDOXOMIL HUMAN PRESCRIPTION DRUG LABEL 1 0527-2425 TABLET, FILM COATED 5 mg ORAL ANDA 31 sections
OLMESARTAN MEDOXOMIL HUMAN PRESCRIPTION DRUG LABEL 1 0527-2425 TABLET, FILM COATED 5 mg ORAL ANDA 31 sections
OLMESARTAN MEDOXOMIL HUMAN PRESCRIPTION DRUG LABEL 1 0527-2426 TABLET, FILM COATED 20 mg ORAL ANDA 31 sections
OLMESARTAN MEDOXOMIL HUMAN PRESCRIPTION DRUG LABEL 1 0527-2426 TABLET, FILM COATED 20 mg ORAL ANDA 31 sections
OLMESARTAN MEDOXOMIL HUMAN PRESCRIPTION DRUG LABEL 1 0527-2427 TABLET, FILM COATED 40 mg ORAL ANDA 31 sections
OLMESARTAN MEDOXOMIL HUMAN PRESCRIPTION DRUG LABEL 1 0527-2427 TABLET, FILM COATED 40 mg ORAL ANDA 31 sections
Azor HUMAN PRESCRIPTION DRUG LABEL 2 0713-0870 TABLET, FILM COATED 20 mg ORAL NDA 26 sections
Azor HUMAN PRESCRIPTION DRUG LABEL 2 0713-0871 TABLET, FILM COATED 20 mg ORAL NDA 26 sections
Azor HUMAN PRESCRIPTION DRUG LABEL 2 0713-0872 TABLET, FILM COATED 40 mg ORAL NDA 26 sections
Azor HUMAN PRESCRIPTION DRUG LABEL 2 0713-0873 TABLET, FILM COATED 40 mg ORAL NDA 26 sections
Tribenzor HUMAN PRESCRIPTION DRUG LABEL 3 0713-0874 TABLET, FILM COATED 20 mg ORAL NDA 28 sections
Tribenzor HUMAN PRESCRIPTION DRUG LABEL 3 0713-0875 TABLET, FILM COATED 40 mg ORAL NDA 28 sections
Tribenzor HUMAN PRESCRIPTION DRUG LABEL 3 0713-0876 TABLET, FILM COATED 40 mg ORAL NDA 28 sections
Tribenzor HUMAN PRESCRIPTION DRUG LABEL 3 0713-0877 TABLET, FILM COATED 40 mg ORAL NDA 28 sections
Tribenzor HUMAN PRESCRIPTION DRUG LABEL 3 0713-0878 TABLET, FILM COATED 40 mg ORAL NDA 28 sections
Olmesartan Medoxomil HUMAN PRESCRIPTION DRUG LABEL 1 13668-248 TABLET 5 mg ORAL ANDA 21 sections
Olmesartan Medoxomil HUMAN PRESCRIPTION DRUG LABEL 1 13668-248 TABLET 5 mg ORAL ANDA 21 sections
Olmesartan Medoxomil HUMAN PRESCRIPTION DRUG LABEL 1 13668-249 TABLET 20 mg ORAL ANDA 21 sections
Olmesartan Medoxomil HUMAN PRESCRIPTION DRUG LABEL 1 13668-249 TABLET 20 mg ORAL ANDA 21 sections
Olmesartan Medoxomil HUMAN PRESCRIPTION DRUG LABEL 1 13668-250 TABLET 40 mg ORAL ANDA 21 sections
Olmesartan Medoxomil HUMAN PRESCRIPTION DRUG LABEL 1 13668-250 TABLET 40 mg ORAL ANDA 21 sections
OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE HUMAN PRESCRIPTION DRUG LABEL 2 13668-251 TABLET 20 mg ORAL ANDA 20 sections
OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE HUMAN PRESCRIPTION DRUG LABEL 2 13668-251 TABLET 20 mg ORAL ANDA 20 sections
OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE HUMAN PRESCRIPTION DRUG LABEL 2 13668-252 TABLET 40 mg ORAL ANDA 20 sections
OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE HUMAN PRESCRIPTION DRUG LABEL 2 13668-252 TABLET 40 mg ORAL ANDA 20 sections